EP Patent

EP2210890A1 — Oxadiazole derivatives as S1P1 receptor agonists

Assigned to Almirall SA · Expires 2010-07-28 · 16y expired

What this patent protects

New compounds having the chemical structure of formula (I) or pharmaceutically acceptable salts or N-oxides thereof wherein A is selected from the group consisting of -N-, -O- and -S-; B and C independently are selected from the group consisting of -N- and -O-, with the proviso…

USPTO Abstract

New compounds having the chemical structure of formula (I) or pharmaceutically acceptable salts or N-oxides thereof wherein A is selected from the group consisting of -N-, -O- and -S-; B and C independently are selected from the group consisting of -N- and -O-, with the proviso that at least two of A, B and C are nitrogen atoms; G 1 is selected from the group consisting of nitrogen atoms and -CR C - groups, wherein R C represents a hydrogen atom, a halogen atom, a C 1-4 alkyl group or a C 1-4 alkoxy group; R 1 is selected from the group consisting of hydrogen atoms, C 1-4 alkyl groups, C 1-4 alkoxy groups, C 3-4 cycloalkyl groups, and -NR d R e groups wherein R d and R e are independently selected from hydrogen atoms and C 1-4 alkyl groups; R 2 and R 3 are independently selected from the group consisting of hydrogen atoms and C 1-4 alkyl groups; R 4 , R 5 and R 7 are independently selected from the group consisting of hydrogen atoms, halogen atoms, C 1-4 alkyl groups, C 1-4 alkoxy groups and C 1-4 haloalkyl groups; R 6 represents a C 1-4 alkyl group or a C 1-4 hydroxyalkyl group; or R 6 is selected from the group consisting of -S(O) 2 -NR a R b groups, -(CR f R g ) n -(CR h R i ) x -(CR j R k ) y -NR a R b groups, -(CH 2 ) n -NR a R b groups, -O-(CH 2 ) n -NR a R b groups, -(CH 2 ) n -COOH groups, -(CH 2 ) n -NR a -CO-R b' groups, -(CH 2 ) n -NR a -(CH 2 ) p -(NH) q -SO-CH 3 groups and -(CH 2 ) n -CO-NR a R b groups, wherein n, p, x and y are each independently integers from 0 to 3, q is 0 or 1, R f , R g , R h , R i , R j and R k independently represent hydrogen atoms or halogen atoms, R b' is selected from the group consisting of methylsulphonyl groups, C 1-4 alkyl groups, C 1-4 hydroxyalkyl groups, C 1-4 carboxyalkyl groups, and C 1-4 haloalkyl groups; R a and R b are independently selected from the group consisting of hydrogen atoms, methylsulphonyl groups, C 1-4 alkyl groups, C 1-4 hydroxyalkyl groups, C 1-4 carboxyalkyl groups, and C 1-4 haloalkyl groups, or R a and R b together with the nitrogen atom to which they are attached form a 4 to 6 membered, saturated heterocyclic group, which contains, as heteroatoms, one or two nitrogen atoms and which is substituted by a carboxyl group or a C 1-4 carboxyalkyl group; or R c together with R 6 form a C 5-8 carbocyclic ring optionally substituted by - NHR' wherein R' represents a hydrogen atom or a 6 1-4 carboxyalkyl group.

Drugs covered by this patent

Patent Metadata

Patent number
EP2210890A1
Jurisdiction
EP
Classification
Expires
2010-07-28
Drug substance claim
No
Drug product claim
No
Assignee
Almirall SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.